Mersana Therapeutics, Inc. (NASDAQ:MRSN – Free Report) – Investment analysts at Leerink Partnrs increased their Q3 2023 EPS estimates for Mersana Therapeutics in a research note issued to investors on Tuesday, August 8th. Leerink Partnrs analyst J. Chang now expects that the company will post earnings per share of ($0.37) for the quarter, up from their previous estimate of ($0.46). The consensus estimate for Mersana Therapeutics’ current full-year earnings is ($1.70) per share. Leerink Partnrs also issued estimates for Mersana Therapeutics’ Q4 2023 earnings at ($0.13) EPS, FY2023 earnings at ($1.48) EPS and FY2024 earnings at ($0.53) EPS.
Mersana Therapeutics (NASDAQ:MRSN – Get Free Report) last announced its quarterly earnings data on Tuesday, August 8th. The company reported ($0.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.03). Mersana Therapeutics had a negative return on equity of 255.91% and a negative net margin of 555.84%. The firm had revenue of $10.70 million during the quarter, compared to analysts’ expectations of $12.93 million. The business’s quarterly revenue was up 148.8% on a year-over-year basis.
View Our Latest Analysis on Mersana Therapeutics
Mersana Therapeutics Price Performance
Shares of NASDAQ MRSN opened at $1.25 on Friday. Mersana Therapeutics has a twelve month low of $0.80 and a twelve month high of $9.62. The firm has a market cap of $150.64 million, a P/E ratio of -0.61 and a beta of 1.47. The company has a 50 day moving average of $3.83 and a 200 day moving average of $5.08. The company has a quick ratio of 3.38, a current ratio of 3.97 and a debt-to-equity ratio of 0.28.
Institutional Investors Weigh In On Mersana Therapeutics
A number of large investors have recently added to or reduced their stakes in the stock. Prio Wealth Limited Partnership bought a new stake in shares of Mersana Therapeutics during the 4th quarter valued at $138,000. Rhenman & Partners Asset Management AB bought a new stake in shares of Mersana Therapeutics during the 4th quarter valued at $2,344,000. Oversea Chinese Banking CORP Ltd bought a new stake in shares of Mersana Therapeutics during the 4th quarter valued at $249,000. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Mersana Therapeutics by 34.7% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 45,521 shares of the company’s stock valued at $267,000 after acquiring an additional 11,734 shares during the period. Finally, Boulder Hill Capital Management LP bought a new stake in shares of Mersana Therapeutics during the 4th quarter valued at $135,000. Institutional investors own 93.45% of the company’s stock.
Mersana Therapeutics Company Profile
Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has a research and development collaborations with Janssen Biotech, Inc and Merck KGaA, as well as collaboration agreement with Asana BioSciences, LLC for the development of ADC product candidates.
Featured Articles
- Five stocks we like better than Mersana Therapeutics
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Investing in Coffee: 3 Great Strategies to Consider
- How to Invest in Lithium and Lithium Stocks
- 5 Best Stocks to Buy in a Bear Market
- P/E Ratio Calculation: How to Assess Stocks
- 3 Pharmaceutical Stocks to Buy and Hold for the Long Haul
Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
